DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product Ossi Leppänen2022-03-28T11:32:06+03:00March 28th, 2022| Read More
DelSiTech Announces an Exclusive Licensing and Collaboration Agreement with Visus Therapeutics for the Development of Long-acting Therapies in Ophthalmology Ossi Leppänen2021-08-19T14:00:03+03:00August 19th, 2021| Read More
DelSiTech Ltd Announces the Development of Novel Long-Acting Injectable Biologics for HIV Prevention Marcus Reay2021-03-12T18:12:08+03:00March 12th, 2021| Read More
DelSiTech Ltd Receives Significant Funding for Developing Long-Acting Injectables Marcus Reay2019-05-21T10:46:27+03:00May 21st, 2019| Read More
DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy Lasse Leino2019-04-18T14:22:03+03:00December 18th, 2018| Read More
DelSiTech Ltd and C-Tri Co. Ltd Sign a Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology admin@delsitech.com2018-03-28T07:56:12+03:00December 18th, 2017| Read More
DelSiTech and Bayer Partner to Develop Innovative Drug Delivery Technology for Ophthalmology admin@delsitech.com2018-03-28T07:56:42+03:00September 29th, 2016| Read More
DelSiTech Ltd enters licensing agreement with Solani Therapeutics Ltd in animal health admin@delsitech.com2018-03-28T07:56:54+03:00May 26th, 2015| Read More
